279 related articles for article (PubMed ID: 30929299)
1. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
2. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
4. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
6. Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves.
Wypasek E; Natorska J; Mazur P; Kopytek M; Gawęda B; Kapusta P; Madeja J; Iwaniec T; Kapelak B; Undas A
Vascul Pharmacol; 2020 Jul; 130():106679. PubMed ID: 32387621
[TBL] [Abstract][Full Text] [Related]
7. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban.
Volod O; Rollins-Raval M; Goodwin AJ; Higgins RA; Long T; Chandler WL; Harris NS; Pham HP; Isom JA; Moser K; Olson JD; Smock KJ; VanSandt A; Wool G; Chen D
Arch Pathol Lab Med; 2022 Jan; 146(2):145-153. PubMed ID: 34133726
[TBL] [Abstract][Full Text] [Related]
8. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
Vercruyssen J; Meeus P; Bailleul E
Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models.
Najidh S; Versteeg HH; Buijs JT
Thromb Res; 2020 Mar; 187():18-27. PubMed ID: 31945588
[TBL] [Abstract][Full Text] [Related]
10. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
13. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
14. Measurement and reversal of the direct oral anticoagulants.
Samuelson BT; Cuker A
Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
[TBL] [Abstract][Full Text] [Related]
15. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
Ząbczyk M; Natorska J; Kopytek M; Malinowski KP; Undas A
Arch Pathol Lab Med; 2021 Jan; 145(1):99-104. PubMed ID: 33367661
[TBL] [Abstract][Full Text] [Related]
17. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
18. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
19. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
Lippi G; Favaloro EJ
Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
[TBL] [Abstract][Full Text] [Related]
20. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
